MGX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
-257000
-120.6%
1.2M
-68.1%
3.9M
-54.8%
8.7M
+1.7%
8.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
-257000
-120.6%
1.2M
-68.1%
3.9M
-54.8%
8.7M
+1.7%
8.5M
Operating Expenses
28.5M
+10.4%
25.8M
-8.6%
28.3M
-10.2%
31.5M
+6.8%
29.5M
R&D
22.5M
+16.6%
19.3M
-10.2%
21.5M
-15.0%
25.3M
+12.3%
22.5M
SG&A
6.0M
-8.1%
6.5M
-3.6%
6.8M
+9.0%
6.2M
-11.1%
7.0M
Operating Income
-28773000
-17.0%
-24587000
-0.9%
-24367000
-6.7%
-22839000
-8.8%
-20987000
EBITDA
-27508000
-18.0%
-23312000
-1.1%
-23067000
-7.2%
-21515000
-9.5%
-19652000
Net Income
-27482000
-19.2%
-23059000
-2.4%
-22528000
-10.5%
-20393000
-2.4%
-19908000
EPS (Basic)
$-0.73
-19.7%
$-0.61
-1.7%
$-0.60
-9.1%
$-0.55
-1.9%
$-0.54
EPS (Diluted)
$-0.73
-19.7%
$-0.61
-1.7%
$-0.60
-9.1%
$-0.55
-1.9%
$-0.54
Shares (Diluted)
37.7M
+0.2%
37.6M
+0.3%
37.5M
+0.3%
37.3M
+0.5%
37.2M
Metagenomi Therapeutics (MGX) โ€” Financials